180 Life Sciences % des Leerverkaufs (short % of float)

Was ist das % des Leerverkaufs (short % of float) von 180 Life Sciences?

% des Leerverkaufs (short % of float) von 180 Life Sciences Corp. ist 2.42%

Was ist die Definition von % des Leerverkaufs (short % of float)?



% des Leerverkaufs (Short % of Float) ist die Menge der Aktien, die im Leerverkauf verkauft worden sind, die im Vergleich zum Float in Prozent ausgedrückt wird.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% des Leerverkaufs (short % of float) von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences

Was macht 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Unternehmen mit % des leerverkaufs (short % of float) ähnlich 180 Life Sciences